UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from ____________ to ____________ Commission File Number: 001-40775 (Mark One) ALPHA MODUS HOLDINGS, INC. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) For the quarterly period ended September 30, 2025 (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SECTION ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) Delaware 86-3386030 (I.R.S. Employer Identification No.) 20311 Chartwell Center Dr., #1469 Cornelius, NC 28031 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transi ...

Sales Performance - The Company reported a decrease in sales for EWCP products due to decreased customer orders, while TPA products saw an increase in customer orders [78]. - Three customers accounted for 65% of product sales during the three months ended September 30, 2025, compared to 60% in the same period of 2024 [81]. Financial Performance - Gross profit as a percentage of sales decreased by 20% due to increased costs associated with scaling up new products [78]. - Cash provided by operating activities for the nine months ended September 30, 2025, was $6,757,198, down from $7,787,989 in 2024 [84]. - Working capital as of September 30, 2025, was $21,780,752, a decrease from $22,714,190 as of December 31, 2024 [84]. - Interest income increased due to rising interest rates [79]. Future Outlook - The Company anticipates no significant capital requirements for the twelve months ending September 30, 2026 [85]. - The Company has sufficient cash resources to meet future commitments and cash flow requirements for the coming year [84]. Research and Development - Research and development expenses increased due to successful project completions in 2025 [80]. One-time Events - The Company experienced a one-time loss on the sale of 30.1% of a Florida-based LLC in 2024 [79].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40386 ONEMEDNET CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 86-2076743 (State or other juris ...

Satellite Launch and Technology - Sidus Space successfully launched three hybrid, additively manufactured LizzieSat® satellites equipped with advanced AI edge-computing capabilities in just over 12 months[117]. - The LizzieSat platform includes upgrades such as an AI processor capable of handling 248 trillion operations per second (TOPS) and a payload processor with speeds up to 12 Gb/s[120]. - The modular LizzieSat platform can be customized for various technologies and mission requirements, supporting a broad range of operational and data collection needs[119]. - Successfully launched LizzieSat®-1 in March 2024, LizzieSat®-2 in December 2024, and completed the build and launch of LizzieSat®-3 in Q1 2025, establishing a micro-constellation for near real-time solutions[141]. - Integrated second-generation automated identification system (AIS) technology into the LizzieSat® satellite constellation, enhancing vessel tracking and monitoring solutions[149]. - Expected to launch four to six more LizzieSat® satellites ranging from 100kg to 400kg over the next 24 months, expanding commercial satellite operations[151]. Contracts and Revenue - Signed a preliminary contract valued at $120 million to design and build the first-generation lunar fleet of Data Storage Spacecraft for Lonestar Data Holdings, reinforcing the adaptability of the LizzieSat® platform[141]. - Awarded a $2 million contract from Craig Technologies to manufacture two fleet interactive display equipment (FIDE) pre-production unit main panels for U.S. Navy Propulsion systems[141]. - The data-as-a-service model is subscription-based with multiple price tiers, applicable to government, defense, and commercial customers[123]. - Revenue for the three months ended September 30, 2025, decreased by $570,900, a 31% decline compared to the same period in 2024[177]. - Non-related party revenue fell approximately 68% to about $559,000 for the three months ended September 30, 2025, down from approximately $1.8 million in the same period of 2024[178]. - Related party revenue increased by 562% to approximately $739,000 for the three months ended September 30, 2025, compared to approximately $112,000 in the same period of 2024[178]. Financial Performance - Gross profit decreased 450% for the nine months ended September 30, 2025, resulting in a loss of approximately $3.9 million compared to a loss of approximately $719,000 for the same period in 2024[187]. - Net loss for the nine months ended September 30, 2025, was approximately $18.1 million, an increase of 52% compared to a net loss of approximately $11.8 million in 2024[194]. - Current assets decreased by approximately $1.1 million to approximately $21.1 million as of September 30, 2025, from approximately $22.2 million as of December 31, 2024[200]. - Current liabilities increased by approximately $1.1 million to $15.4 million as of September 30, 2025, primarily due to an increase in asset-based loan liability[201]. - Adjusted EBITDA for the nine months ended September 30, 2025, was approximately $(12.6) million, a decrease of 51% compared to $(8.3) million in 2024[194]. - Cash used in operating activities was approximately $14.1 million, an increase of 37% compared to $10.3 million in the same period of 2024[203]. Manufacturing and Operations - The company operates a 35,000-square-foot manufacturing facility that is ISO 9001:2015 and AS9100 Rev. D certified, supporting the manufacturing, testing, and assembly of space-grade hardware[124]. - Sidus Space's manufacturing capabilities include precision machining, multi-material 3D printing, and a reconfigurable avionics lab for producing space system components[124][130]. - The company aims to expand its space and defense hardware operations from one shift to two and a half shifts, targeting growth in avionics and wire harness divisions[153]. - Established a fully operational mission control center to manage satellite operations and enhance constellation operation capabilities[141]. Market Trends and Growth - The global space economy is projected to reach $1.8 trillion by 2035, growing from $630 billion in 2023, with an average annual growth rate of 9%[167]. - The small satellite market is expected to grow at a CAGR of 16.4%, reaching approximately $30.6 billion by 2034, driven by cost-effectiveness and advances in miniaturization[168]. - The small satellite launch market is projected to grow from $7.6 billion to $28.4 billion, reflecting a 279% increase[172]. - The company is actively expanding its international market presence, signing partnership agreements with companies in Germany, Japan, Bahrain, and India[163]. Intellectual Property and Innovation - Strengthened intellectual property portfolio with the approval of new patents and the publication of a patent application protecting enhanced functionality of the LizzieSat® Modular Satellite Platform System[142]. - The company holds 14 granted patents and 13 pending applications related to space technologies, indicating a strong focus on innovation[157]. Financial Adjustments and Reporting - The company adopted ASC 606 for revenue recognition, which did not have a material impact on the consolidated financial statements[211]. - The company accounts for most fixed price or time and materials contracts as performance obligations satisfied over time, reflecting the right to collect based on services provided[216]. - The provision for expected credit losses on trade receivables is estimated based on historical information and customer solvency, with adjustments for forward-looking information[218]. - The company is evaluating the benefits of relying on exemptions and reduced reporting requirements provided by the JOBS Act as an "emerging growth company"[226].

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40386 ONEMEDNET CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 86-2076743 (State or other juris ...

Mergers and Acquisitions - As of September 30, 2025, NanoVibronix, Inc. completed a merger with ENvue Medical Holdings, resulting in the formation of two wholly-owned subsidiaries: NanoVibronix Ltd. and ENvue Medical Holdings LLC[179]. Financial Performance - For the three months ended September 30, 2025, revenues were approximately $722 thousand, an increase of 92% compared to $376 thousand in the same period of 2024[212]. - Gross profit for the three months ended September 30, 2025, was approximately $189 thousand, a 42% increase from $133 thousand in 2024[214]. - For the nine months ended September 30, 2025, revenues were approximately $2,241 thousand, a 6% increase from $2,114 thousand in 2024[225]. Expenses - Research and development expenses decreased by approximately 11% to $221 thousand for the three months ended September 30, 2025, compared to $249 thousand in 2024[216]. - Selling and marketing expenses surged by approximately 349% to $812 thousand for the three months ended September 30, 2025, from $181 thousand in 2024[218]. - General and administrative expenses increased by approximately 108% to $1,403 thousand for the three months ended September 30, 2025, compared to $673 thousand in 2024[220]. - Research and development expenses for the nine months ended September 30, 2025, increased by approximately 209% to $1,723 thousand from $557 thousand in 2024[229]. - Selling and marketing expenses for the nine months ended September 30, 2025, rose by approximately 245% to $1,878 thousand compared to $545 thousand in 2024[232]. - General and administrative expenses for the nine months ended September 30, 2025, were approximately $4,997 thousand, an increase of 114% from $2,335 thousand in 2024[234]. Cash Flow and Financing - As of September 30, 2025, the company reported a cash balance of approximately $6,980 thousand after incurring approximately $6,696 thousand in cash used in operating activities[240]. - As of September 30, 2025, the company had cash and cash equivalents of approximately $6,980 thousand, a significant increase from approximately $752 thousand as of December 31, 2024[246]. - Cash used in operating activities for the nine months ended September 30, 2025, was approximately $6,696 thousand, compared to approximately $1,968 thousand for the same period in 2024[247]. - Cash provided by financing activities during the nine months ended September 30, 2025, was approximately $12.8 million, primarily from net proceeds of $17.1 million from the issuance of common stock, preferred stock, and warrants[248]. Compliance and Regulatory Matters - The company received a compliance extension from Nasdaq to demonstrate adherence to the minimum bid price and equity requirements by March 31, 2025[189]. - On April 9, 2025, the company demonstrated compliance with Nasdaq's bid price and equity requirements, avoiding delisting[190]. - The company is subject to a one-year mandatory panel monitor following compliance with Nasdaq requirements[191]. - The company has identified inaccuracies in its 510(k) application for the PainShield MD Plus product and intends to halt future sales of the product[251]. - The company is subject to risks common in the biopharmaceutical industry, including regulatory approvals and competition from new products[252]. Capital Requirements and Future Outlook - The company's future capital requirements will depend on the successful commercialization of its products and the development of future product offerings[249]. - The company anticipates that future operating results will be subject to quarterly variations based on various factors, including distributor ordering patterns and regulatory approvals[250]. Asset Changes - Major changes in assets are primarily attributable to a merger, reflecting the revaluation and consolidation of assets[244]. - Cash provided in investing activities was approximately $111 thousand for the nine months ended September 30, 2025, mainly from cash acquired in the merger[247]. - The company has no off-balance sheet transactions or obligations that may materially affect its financial condition as of September 30, 2025[243]. Stock and Offerings - In September 2025, the company conducted a registered direct offering, issuing 74,114 shares of common stock and prefunded warrants for a total net proceeds of approximately $1.88 million[181]. - The Series H Initial Closing on July 22, 2025, generated gross proceeds of $8 million from the sale of 8,889 shares of Series H Convertible Preferred Stock[185]. - The Series H Purchase Agreement allows for the potential issuance of up to $44 million in additional Series H Preferred Stock over a 36-month period[184]. - The company executed a 1-for-10 reverse stock split effective August 11, 2025, to comply with Nasdaq listing requirements[182].

Financial Performance - Revenue for Q3 2025 totaled $146,000, a 15.9% increase from $126,000 in Q3 2024[6] - Gross loss for Q3 2025 was $145,000, compared to a gross profit of $44,000 in Q3 2024, primarily due to $230,000 in inventory reserves[6] - Operating expenses increased to $2.3 million in Q3 2025 from $1.5 million in Q3 2024, attributed to the addition of the biopharma business and increased corporate costs[6] - Net loss for Q3 2025 was $2.6 million, compared to a net loss of $1.4 million in Q3 2024[9] - Tivic's gross margin, excluding inventory reserves, was 42% in Q3 2025, compared to 35% in Q3 2024[6] Cash Position - Cash and cash equivalents as of September 30, 2025, were $3.5 million, up from $2.0 million at December 31, 2024[9] Business Development - Tivic completed the transfer of two INDs from Statera Biopharma, enabling clinical trials for Entolimod in neutropenia and cancer-related conditions[6] - The company successfully completed cell line verification, a key step for cGMP manufacturing, necessary for filing a biologics license application with the FDA[6] - The company executed the write-down of ClearUP inventory, resulting in $230,000 of cost of goods sold and $117,000 of other expenses[9] - The company is advancing discussions for deploying Entolimod as a military countermeasure and stockpile drug[6]

Financial Performance - Revenue for the three months ended September 30, 2025 decreased by 97.6% to $72,377 compared to $3,052,727 for the same period in 2024, primarily due to cash constraints limiting inventory purchases [296] - Gross profit for the three months ended September 30, 2025 was $426, resulting in a gross margin of 0.6%, down from 7.5% in the same period of 2024 [299] - Revenue for the nine months ended September 30, 2025 decreased 80.8% to $1,663,205 compared to $8,662,414 for the same period in 2024 [310] - Gross profit was $204,684 for the nine months ended September 30, 2025, down from $992,650 in 2024, while gross margin increased to 12.3% from 11.5% [313] - Net loss for the three months ended September 30, 2025 was $2,170,789, a decrease of $579,547 from the net loss of $2,750,336 for the same period in 2024 [307] - Net loss for the nine months ended September 30, 2025 was $5,961,537, a decrease of $863,924 from the net loss of $6,825,461 in 2024 [322] Expenses and Costs - Selling, general and administrative expenses decreased by 44.9% to $1,205,125 for the three months ended September 30, 2025, compared to $2,186,953 for the same period in 2024 [300] - Operating expenses decreased 27.0% to $3,849,952 in 2025, primarily due to a 32.0% reduction in selling, general and administrative expenses [314] - Provision for credit losses increased by 246.5% to $126,824 for the three months ended September 30, 2025, compared to $36,597 for the same period in 2024 [301] - Provision for credit losses increased 401.9% to $306,091 in 2025, reflecting higher estimated credit risk associated with outstanding receivables [316] Cash Flow and Financing - Cash and cash equivalents at the end of the period were $61,450, compared to $40,114 at the end of September 30, 2024 [333] - Net cash used in operating activities was approximately $1.8 million for the nine months ended September 30, 2025, down from $3.2 million in 2024 [334] - The company has a $20 million equity financing program declared effective by the SEC to address liquidity needs [324] - The company has entered into a securities purchase agreement for $2 million with Y.K. Capital Management, Inc., with an initial payment of $500,000 received [327] - Net cash provided by financing activities for the nine months ended September 30, 2025, was approximately $2.3 million, driven by proceeds from Series A and D preferred stock, warrant exercises, and convertible notes borrowing [338] - In comparison, net cash provided by financing activities for the nine months ended September 30, 2024, was approximately $3.0 million, mainly from short-term loans and public offerings [339] Business Development and Strategy - The company plans to enter the electric vehicle market by distributing medium-sized trucks in Latin America and developing indoor growing systems within these trucks [280] - The company is investing in Future Tech Inc., a Bitcoin mining and data center business, and plans to enter the field of Digital Treasury Management focusing on XRP [280] - The company has added new products including organic and non-organic fertilizers and dehumidifiers to enhance its offerings [283] - The company is developing proprietary "all in one" automated and robotic indoor growing systems currently in design and testing phases [286] - The company entered into a strategic cooperation agreement with Sinoinnovo Technology for sourcing grow light systems for distribution in the U.S. and Europe [289] Customer Metrics - The number of customers decreased from 114 in 2024 to 68 in 2025, with average revenue per customer dropping from $75,986 to $24,459 [311] Accounting and Valuation - The company follows ASC 606 for revenue recognition, recognizing revenue upon satisfying performance obligations related to product sales [344] - Accounts receivable are stated at expected collectible amounts, with an allowance for expected credit losses based on historical and forecasted conditions [354] - Inventory is valued at the lower of cost and net realizable value, using the weighted average costing method, and is regularly reviewed for obsolescence [355] - The company reviews long-lived assets for impairment annually and determined no impairment as of September 30, 2025, with estimated disposal values exceeding carrying values [357] Non-Cash Transactions - Non-cash transactions included asset acquisitions via preferred stock and convertible note issuances totaling approximately $12.8 million related to Zak Properties, LLC [340] Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements that could materially affect its financial condition or results of operations [342]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-42889 Commercial Bancgroup, Inc. (Exact Name of Registrant as Specified in its Charter) | Tennessee | 62-1039469 | | --- | --- | | (State or other jurisdiction ...